Search
Anteris Technologies Global Corp
AVRAdd to Watchlist
10.240USD
+0.300+3.02%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
995.66MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.02%
5 Days
-1.54%
1 Month
+12.53%
6 Months
+108.13%
Year to Date
+105.21%
1 Year
+175.27%
Key Figures
9.960Open
10.260High
1.26MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.30%Turnover Ratio
9.940Prev. Close
9.835Low
10.07MTurnover
LossP/E Static
3.58P/B
0.00%Div Yield TTM
-53.85%ROA
9.79052wk High
1.00Volume Ratio
-76.29MNet Profit
97.23MShares
-2.2208EPS TTM
--Beta
-59.25%ROE
2.85052wk Low
4.28%Amplitude
76.92%Gross Margin
995.66MMarket Cap
2.39Reward/Risk
4.64%Risk Rate
TradingKey Stock Score of Anteris Technologies Global Corp
Currency: USD Updated: 2026-07-01Key Insights
Anteris Technologies Global Corp's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 92 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.75.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Anteris Technologies Global Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Anteris Technologies Global Corp Highlights
StrengthsRisks
Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.91M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.91M.
Undervalued
The company’s latest PE is -4.48, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 37.99M shares, increasing 28.83% quarter-over-quarter.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
14.750
Target Price
+50.82%
Upside Space
Anteris Technologies Global Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Anteris Technologies Global Corp Info
Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
Ticker SymbolAVR
CompanyAnteris Technologies Global Corp
CEOPaterson (Wayne G)
Websitehttps://anteristech.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.76%
+3.40%
+1.10%
-2.09%
+3.50%Popular Instruments
FAQs
What is the current price of Anteris Technologies Global Corp (AVR)?
The current price of Anteris Technologies Global Corp (AVR) is 9.94.
What is the symbol of Anteris Technologies Global Corp?
The ticker symbol of Anteris Technologies Global Corp is AVR.
What is the 52-week high of Anteris Technologies Global Corp?
The 52-week high of Anteris Technologies Global Corp is 9.79.
What is the 52-week low of Anteris Technologies Global Corp?
The 52-week low of Anteris Technologies Global Corp is 2.85.
What is the market capitalization of Anteris Technologies Global Corp?
The market capitalization of Anteris Technologies Global Corp is 967.58M.
Is Anteris Technologies Global Corp (AVR) currently rated as Buy, Hold, or Sell?
According to analysts, Anteris Technologies Global Corp (AVR) has an overall rating of Buy, with a price target of 14.75.
What is the Earnings Per Share (EPS TTM) of Anteris Technologies Global Corp (AVR)?
The Earnings Per Share (EPS TTM) of Anteris Technologies Global Corp (AVR) is -2.55.